Results for “NHS”

The provision of Generic Drugs - Injections/Infusions

NHS Essex Integrated Care Board is undertaking a Competitive Process under the Health Care Services (Provider Selection Regime) Regulations 2023 for the award of a General Medical Services (GMS) contract for Tollgate Practice, Stanway, Colchester. The Authority seeks a suitably qualified provider to deliver primary medical services to a registered patient population of approximately 10,206 patients. Services will be provided under a nationally prescribed GMS contract from the existing practice premises and will include the delivery of core primary medical services, management of the registered patient list, clinical governance, safeguarding, information governance and integration with local health and care services. This procurement is being undertaken to secure the long-term provision of stable, resilient and high-quality primary medical services for the local population. Due to the fixed practice location, established patient list and requirement for uninterrupted service delivery, bidders must demonstrate the ability to mobilise and maintain an appropriately qualified workforce and robust governance arrangements from contract commencement. The contract will be awarded following evaluation against the key criteria set out in the Health Care Services (Provider Selection Regime) Regulations 2023. The estimated contract value is £21,896,491.60, calculated using a notional 20-year term for valuation purposes only. The contract itself is a perpetual GMS contract and is not time limited. Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: [email protected]

NHS Essex Integrated Care Board (the Authority) is undertaking a competitive procurement process under the Health Care Services (Provider Selection Regime) Regulations 2023 for the award of a General Medical Services (GMS) contract for Tollgate Practice, located in Stanway, Colchester.<br/><br/>The procurement seeks to identify a suitably qualified and experienced provider to deliver safe, effective, sustainable and accessible primary medical services to the registered patient population of Tollgate Practice. The commercial schedule currently assumes an actual patient list of 10,206 and a weighted patient list of approximately 8,832, subject to future list size adjustments in line with national General Medical Services arrangements.<br/><br/>The successful provider will be required to deliver the full range of services associated with a nationally prescribed GMS contract, including management of a registered patient list, provision of core primary medical services, clinical governance, workforce management, patient access requirements and integration with local health and care services.<br/><br/>The procurement is being undertaken following caretaker arrangements that were implemented to maintain continuity of services whilst the practice recovered from historical quality and regulatory concerns.<br/><br/>The contract is intended to secure the long-term provision of stable and resilient primary medical services beyond the caretaker period.

This project aims to procure a HTP DNA extraction solution, ensuring continuity and scalability of DNA-based diagnostic services

This Invitation to Tender (ITT) is issued by NHS Wales Shared Services Partnership Procurement Services (hosted by Velindre University NHS Trust) ("NWSSP") on behalf of Hywel Dda University Health Board ("HDUHB"), which will act as the lead contracting authority and enter into the resulting agreement. Hywel Dda University Health Board, acting on behalf of Betsi Cadwaladr University Health Board, Cwm Taf Morgannwg University Health Board and Swansea Bay University Health Board, is seeking to procure a modern Community Information System to replace the existing Wales Community Care Information System (WCCIS), which is approaching end of life. The procurement presents a significant opportunity to deliver a strategic digital care record solution supporting integrated health, community, mental health and social care services across Wales. The Authority is seeking a cloud-ready, secure, resilient and highly interoperable platform capable of supporting a shared digital care record, mobile working, multidisciplinary care planning, advanced reporting, and seamless integration with national and local health and care systems. Suppliers will be expected to demonstrate strong implementation and data migration capability, alignment with NHS Wales Digital Architecture principles, robust cyber security and information governance arrangements, and a commitment to innovation, service transformation and long-term scalability. The solution will support a broad range of community services, including Health Visiting, School Nursing, Children's Community Nursing, Safeguarding and Community Nursing services, with the potential for future expansion. The resulting contract will play a key role in enabling person-centred, digitally enabled integrated care, improving information sharing, reducing administrative burden and supporting better outcomes for citizens across Wales.

NHS Hampshire and Isle of Wight Integrated Care Board would like to invite bids for the delivery of a new service that will provide an adult community audiology service to deliver assessment, diagnosis, and management of hearing loss for eligible adults, in accordance with NHS England standards, best practice, and local commissioning requirements. This service is required across the entire Hampshire and Isle of Wight footprint.

1.1 National/local context and evidence base This service specification sets out the principles and values by which the Oxfordshire Non-Clinical Crisis Alternative will meet the ambitions from NHS England (NHSE) and the NHS Long Term Plan for Mental Health. As part of the Urgent Care Pathway, it will meet the ambitions of NHS England as articulated in Fit for the Future: The 10-Year Health Plan for England and the NHS Medium Term Planning Framework 2026/27 to 2028/29. These strategic documents establish the expectation of neighbourhood health services operating as alternatives to hospital centred crisis response and integration across health and social care. In the context of this specification, a mental health crisis is when someone is experiencing a period of acute psychological distress, or an acute mental health problem which may or may not have been given a formal diagnosis. The crisis may be a sudden deterioration of an existi

Adult MH - Crisis Alternative (Safe Haven) a Non-Clinical Healthcare Alternative to Urgent Care Service to support Oxfordshire's urgent and emergency care system. The service is intended to prevent avoidable emergency department attendance and hospital admissions, improving patient outcomes and system efficiency. The key objectives are: -Improve clinical outcomes and patient experience -Reduce pressure on ED and inpatient services -Deliver value for money and system efficiency -Support integrated urgent care pathways Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: [email protected]

NHS National Framework for Generics Orals, Non-Parenteral & Housekeeping Offer Reference number: CM/PHG/25/5738 Period of framework agreement: Dates detailed below, with an option or options to extend (at the authority’s discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/25/5738/01 - Oral & Non-Parenteral Products: CESW (Central/Midlands and Southwest): 1st June 2027 to 31st May 2030 (36 months) LSNE (London South and Northeast 1st June 2027 to 31st May 2030 (36 months) NWLN (Northwest and London North): 1st June 2027 to 31st May 2030 (36 months) CM/PHG/25/5738/02 – Hospital Only (Orals, Non-Parenteral & Housekeeping) Products: DCE (Central/Midlands) & DSW (Southwest): 1st June 2027 to 30th September 2029 (28 months) DLS (London South) & DNE (Northeast): 1st June 2027 to 31st May 2028 (12 months) DNW (Northwest) & DLN (London North): 1st June 2027 to 31st January 2029 (20 months)

QEHKL239 Roof Re-covering Works and services

CM-MSR-24-5704 - Home Delivery Service - Lysosomal Storage Disorders - July 2027. NHS National Framework agreement Home Delivery Lysosomal Storage Disorders in England and Scotland. Offer Reference number: CM-MSR-24-5704 Period of framework agreement 01 July 2027 to 30 June 2029 With option(s) to extend at the authority's discretion for a period or periods up to a total of 24 months.

This is a Community Tier 3 Dermatology Service. This service aims to address the specific healthcare needs of patients who require access to dermatology services where the service is delivered across the Greater Manchester conurbation. The Specification contains the requirements to ensure the delivery of a local, effective, integrated patient centred, community-based, dermatology service that gives timely advice, assessment, diagnosis and treatment. This is to be delivered in line with the GM strategic aim to deliver increased quality of care closer to patient's' homes. The Contract to be awarded as a result of this Procurement will have an initial term of three years commencing from the Commencement Date (as defined in the Contract) which is expected to be on 1 April 2027. The Authority may extend the initial term of the Contract by a further period of two years to a maximum term of five years. The indicative overall contract value is £26,975,375.25 for the initial three-year contract term and £17,983,583.50 for the optional two-year extension period, with an estimated annual value of £8,991,791.75 and an anticipated maximum total value of £44,958,958.75 including extensions. For full details of the Service and any additional information regarding this Procurement please see link to the Specification and Invitation to Tender documentation that can be accessed via SAP Ariba. Invitation to Tender documentation can be accessed via SAP Ariba reference Doc3193557990 at the link available in section I.III

The Norfolk and Suffolk Integrated Care Board is looking to commission the University of Suffolk Dental and Student Education Service. This service will be a Personal Dental Services (PDS) Agreement (contract) to deliver primary care dental services, host placements and supervise undergraduates on the University of Suffolk BSc Dental Hygiene and Therapy course at the University of Suffolk James Hehir building in Ipswich.

The NHS Hampshire and Isle of Wight Integrated Care Board (HIOW ICB) are seeking a provider for their Community Musculoskeletal Service.

The contract for the Infection and Sepsis Audit - Acute care settings (NISA-Acute) will initially be delivered for NHS-funded care in England and Wales for a period of three years, at a maximum total budget of up to £ 1,146,300.00 excl VAT and £1,375,560.00 with VAT. Bids exceeding these limits will be rejected. All pricing submissions must be in regard to this 'core' value, and not inclusive of any extension costs or aspirational intent costs, i.e. Please only submit a cost schedule up to the maximum core value of £ 1,146,300.00 excl VAT and £1,375,560.00 with VAT. The maximum budget ‘core’ value excludes the potential two year extension and aspirational intent as described in section 14.3 of Annex A - Service Specification. Please note, there is no commitment by the Authority at this stage to include any of the below aspirational intent. Taking this aspirational intent into account, including the possibility that a contract extension may be offered for an additional 24 months, the potential ceiling value is £8,988,606.00 GBP including VAT. This is a new national clinical audit for severe infection and sepsis in acute NHS hospital settings. The aim is to provide benchmarked infection and sepsis care data to identify variation and drive improvement over time. Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. While it is an unusual complication of developing an infection, it can be triggered by any infection. When people die from an infection, it is most commonly due to sepsis. Sepsis is complex and hard to diagnose, with no single test and symptoms that overlap with other conditions (NHS England Modern Service Framework, 2026) Severe infections may lead to the development of sepsis, particularly in at-risk groups, and are one of the most common reasons for emergency admission to hospital. Both infection and sepsis are major causes of morbidity and mortality in the UK, and costly to the NHS and wider economy: In 2025 there were over 23,000 deaths involving sepsis (Office for National Statistics). Patients and carers who we engaged with as part of specification development told us of long-term impacts that some sepsis survivors experience, from reduced mobility and cognitive difficulties, to loss of limbs or vision impairments. Each year, the NHS in England spends over £1billion on sepsis care, and over £6.5billion on infection care. Wider economic costs are estimated at £10-15billion annually (York Health Economics Consortium, 2017). 1,300 clinical negligence claims were made regarding sepsis from 2020/21 to 2024/25, costing £65.3m in litigation. Most claims relate to delays and failures in treatment and diagnosis. Several major healthcare initiatives have been launched to help improve care related to sepsis and severe infection, including: NHS England’s sepsis Modern Service Framework (MSF), which aims to reduce death, life-threatening complications and long-term impact from sepsis and severe infection by at least 25% by 2035, as well as reducing health inequalities (published July 2026). NHS England’s National Improvement Programme for ‘Optimising the acute management of sepsis’ (as part of the MSF activities). The National Patient Safety Plan for NHS Wales 2026-2031, which includes sepsis care. The UK Anti-Microbial Resistance (AMR) National Action Plan, which pledges to strengthen infection prevention and control (IPC) and antimicrobial stewardship (AMS) in health and social care settings New NICE guidelines for recognition, diagnosis and early management of suspected sepsis, published in November 2025 (NG253-NG255) Establishing the NISA-Acute audit is a key ambition of the NHS England sepsis MSF, and the audit will be expected to align closely with all the initiatives listed above. The audit funders have selected ‘early stages of care’ as the initial priority for this audit because this is a critical point for effective severe infection management and the swift identification and treatment of sepsis. Prompt, effective treatment is vital to improving outcomes, and both Prevention of Future Death (PFD) reports and Health Services Safety Investigations Body (HSSIB) investigations have highlighted opportunities to improve care in this area.

Project title: NHS National Framework for Lenvatinib Offer reference number: CM/TNS/26/5751 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/26/5751 Lenvatinib Lot 1 CESW: 01/06/2027 to 31/01/2029 (20 months) Lot 2 NWLN: 01/06/2027 to 30/09/2028 (16 months) Lot 3 LSNE: 01/06/2027 to 31/05/2028 (12 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

NHS South West London Integrated Care Board (the Authority) is seeking to commission a Mental Health Support Team (MHST) service comprising 25 operational and developing MHSTs across the six boroughs. The service will provide prevention and early intervention mental health support through a standardised and equitable MHST offer, in accordance with the specified requirements, to improve access to care, reduce health inequalities, and deliver improved outcomes for children and young people across South West London. Procured through a competitive process under the Health Care Services (Provider Selection Regime) Regulations 2023, the Authority intends to appoint a Lead Provider with overall accountability for the governance, management, and delivery of the service. The Lead Provider will oversee all operational and developing MHSTs across South West London and will be responsible for the mobilisation, delivery and service integration of future MHST teams required as part of the planned expansion to achieve 100% MHST coverage across South West London by December 2029. The decisions applicable to this Procurement will be made by the Authority. The Procurement is being managed by NHS London Commercial Hub (NHS LCH) hosted by NHS North East London, on behalf of the Authority, in connection with an Invitation to Tender (ITT) exercise that is being conducted, based on the competitive process under the Health Care Services (Provider Selection Regime) regulations 2023 ("the Regulations"(as amended). None of the references to "ITT", "Bid", or the use of the term "tender process", or any other indication, shall be taken to mean that the Authority intends to hold itself bound to any of the Regulations, save those applicable to PSR provisions regarding the Competitive Process. Further information regarding the Authority is available from: https://www.southwestlondon.icb.nhs.uk/ The lifetime Value of the contract is £89,916,960 excluding VAT. The contract term is for three (3) years with an option for extension of further three (1 + 1 + 1) years at the sole discretion of the Authority. The contract will start on 01/04/2027 and end 31/03/2030, if the 1 + 1 + 1 optional extensions are utilised the maximum contract end date will be 31/03/2033. The maximum duration of the contract is 6 years (72 months). Further details of the procurement, including service requirements are included in the procurement documents.

Gloucestershire Health and Care NHS Foundation Trust ("the Authority") is seeking to appoint a suitably qualified and experienced provider for the delivery of Physical Pharmacy Services across its Physical Health services within Gloucestershire. The Authority delivers a diverse range of community-based, outpatient, rehabilitation, intermediate care, and inpatient physical healthcare services. The successful contractor will be required to provide a comprehensive, safe, effective, and patient-centred pharmacy service that supports the delivery of high-quality clinical care, medicines optimisation, and statutory compliance across the Trust's physical health portfolio. The service will be expected to provide expert pharmacy support, including but not limited to medicines management, medicines optimisation, clinical pharmacy input, governance and assurance activities, medicines reconciliation, prescribing support, staff training and education, audit and quality improvement activities, and specialist pharmaceutical advice to multidisciplinary teams. The Authority is seeking a provider that can demonstrate: Extensive experience in delivering pharmacy services within NHS and/or comparable healthcare environments; Strong clinical governance and medicines safety arrangements; - A skilled and resilient workforce capable of supporting services across multiple care settings; - The ability to work collaboratively with clinical teams and system partners; - Innovative approaches to medicines optimisation and service improvement; - Robust digital capabilities, reporting arrangements, and data management processes; and - A commitment to delivering high-quality patient outcomes, value for money, sustainability, and social value. The contract will support the Authority's strategic objectives by ensuring that patients receive safe, effective, and timely pharmaceutical care, while promoting the appropriate use of medicines and supporting service efficiency across physical healthcare pathways. The procurement will be conducted through an open and transparent competitive process. Tender submissions will be evaluated on the basis of the Most Advantageous Tender (MAT), taking into account quality, service delivery, clinical governance, social value, and commercial considerations. Full details of the evaluation methodology and award criteria will be provided within the procurement documentation. The successful provider will be expected to mobilise and maintain a service model that is responsive to changing patient needs, workforce challenges, regulatory requirements, and developments in pharmacy practice throughout the contract term. Further information relating to the scope of services, contract requirements, performance standards, Key Performance Indicators (KPIs), and contractual arrangements will be included within the Invitation to Tender documentation. Registration and documentation will be available for suppliers on Monday 21st September 2026.

The North East & Yorkshire NHS Pharmaceutical Purchasing Consortium (NEYPPC) intend to establish a Framework Agreement for the provision of High Tech Homecare Medicines Services. The scope of this procurement will encompass all High Tech Homecare Medicines Services required by member Trusts within the NEY region, while also allowing access for non-member Trusts. Access for non-member Trusts will be available to any publicly funded entity, subject to prior approval from the Authority. The expectation is that the Framework will be multi-award, structured into the following Lots: Lot HT26-A: Unlicensed Compounded Desferrioxamine Homecare Medicines Services Lot HT26-B: Unlicensed Compounded Antimicrobial Homecare Medicines Services Lot HT26-C: Unlicensed Compounded Chemotherapy and Monoclonal Antibody Homecare Medicines Services Lot HT26-D: Other Unlicensed Compounded Homecare Medicines Services Lot HT26-E: Metabolic Disorders Homecare Medicines Services Medicines Lot HT26-F: Other Non-compounded High Tech Homecare Medicines Services

This tender is for the provision of antiviral medicines for the treatment of Hepatitis C (HCV) to NHS Wales.